相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Proposal Regarding Reporting of In Vitro Testing Results
Malcolm A. Smith et al.
CLINICAL CANCER RESEARCH (2013)
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy
S. E. M. Herman et al.
LEUKEMIA (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
Sabine Ponader et al.
BLOOD (2012)
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
Martin F. M. de Rooij et al.
BLOOD (2012)
New Strategies in the Treatment of Mantle Cell Lymphoma
Changchun Deng et al.
CLINICAL CANCER RESEARCH (2012)
Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Yair Herishanu et al.
BLOOD (2011)
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
Brian J. Lannutti et al.
BLOOD (2011)
SYK inhibition and response prediction in diffuse large B-cell lymphoma
Shuhua Cheng et al.
BLOOD (2011)
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E. M. Herman et al.
BLOOD (2011)
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
Julia Hoellenriegel et al.
BLOOD (2011)
Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals
Alison M. McCaig et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Philip C. Amrein et al.
CLINICAL CANCER RESEARCH (2011)
Response to Dasatinib in a Patient with Concomitant Chronic Myeloid Leukemia and Chronic Lymphocytic Leukemia
Mariana Serpa et al.
ACTA HAEMATOLOGICA (2010)
B Cell Signaling and Fate Decision
Tomohiro Kurosaki et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 28 (2010)
Early Events in B Cell Activation
Naomi E. Harwood et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 28 (2010)
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Jonathan W. Friedberg et al.
BLOOD (2010)
The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling
Mirza Suljagic et al.
BLOOD (2010)
PI3K/p110δ is a novel therapeutic target in multiple myeloma
Hiroshi Ikeda et al.
BLOOD (2010)
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia
Maike Buchner et al.
BLOOD (2010)
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
Sarah E. M. Herman et al.
BLOOD (2010)
Activities of SYK and PLCγ2 Predict Apoptotic Response of CLL Cells to SRC Tyrosine Kinase Inhibitor Dasatinib
Zibo Song et al.
CLINICAL CANCER RESEARCH (2010)
Mechanisms of Disease: Aggressive Lymphomas.
Georg Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia
Carlo Calissano et al.
BLOOD (2009)
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406
Maite P. Quiroga et al.
BLOOD (2009)
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance
Antonina V. Kurtova et al.
BLOOD (2009)
Early events of B-cell receptor signaling are not essential for the proliferation and viability of AIDS-related lymphoma
P. Lu et al.
LEUKEMIA (2009)
Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells
S. Gobessi et al.
LEUKEMIA (2009)
Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles
M. Plander et al.
LEUKEMIA (2009)
The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells
Pablo G. Longo et al.
BLOOD (2008)
The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVHgenes
Aditya Veldurthy et al.
BLOOD (2008)
Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro
Lilian Amrein et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Novel insights in chronic lymphocytic leukemia: Are we getting closer to understanding the pathogenesis of the disease?
Federico Caligaris-Cappio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib
C. Yang et al.
LEUKEMIA (2008)
SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma
Linfeng Chen et al.
BLOOD (2008)
CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells
Rajendra N. Damle et al.
BLOOD (2007)
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma. B cells from tumor-infiltrating nonmalignant B cells
Jonathan M. Irish et al.
BLOOD (2006)
Mechanisms of disease: Chronic lymphocytic leukemia
N Chiorazzi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
B cell antigen receptor signaling 101
JM Dal Porto et al.
MOLECULAR IMMUNOLOGY (2004)
Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins
GF Widhopf et al.
BLOOD (2004)
分享论文
